Delivery Order SPE2DB22D1202-SPE2DB25FURL4

Award Date 2/3/25
Potential Completion Date 2/25/25
Potential Value $1K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,659.62 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract has a completion date of January 3, 2025 and was awarded on December 11, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML medical supplies. The $3,886.54 Firm Fixed Price Delivery Order was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency. The contract has an ultimate completion date of January 2, 2025 and was awarded on December 10, 2024. The contract is not designated as a set-aside. Amerisourcebergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,261.69, is a delivery order for the supply of HYPERRAB 300 UNIT/ML VIAL medical products. The contract has a firm fixed price pricing type and a completion date of March 27, 2023. This award is associated with a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,490.29 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 3ML medical products. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $11,997.08 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product, with an ultimate completion date of August 23, 2024. The contract does not have any set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Amerisourcebergen Corporation. The $9,391.75 Delivery Order is for the supply of HYPERRAB 300 UNIT/ML VIAL 5ML, a pharmaceutical product. The contract is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2025. This...
This federal contract award, valued at $14,326.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML, a medical product, and has a completion date of March 10, 2025. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,860.95 delivery order contract is for the supply of HYPERRAB 300 UNIT/ML VIALML, a specialty medication. The contract is a firm fixed-price, delivery order with an ultimate completion date of April 9, 2024. No set-aside designation was used for this award. Amerisourcebergen holds a $999,999,999 Indefinite...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,744.80, is for the delivery of HYPERRAB 300 UNIT/ML VIAL 5ML medical supplies. The contract is not set-aside and has an ultimate completion date of June 25, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,721.90 firm fixed-price delivery order is for the supply of HYPERRAB 300 UNIT/ML VIALML, a medical product, with a period of performance through November 12, 2024. The contract is an indefinite delivery vehicle and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB25FURL4
    Delivery Order

This federal contract award is a $1,039.53 Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of HYPERRAB 300 UNIT/ML VIALML, a medical product, with a completion date of February 25, 2025. The contract is not designated with a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally.

Generated 5/5/25, 9:42 AM